Our key objective was to perform a collaborative meta-analysis incorporating all of the available evidence from all large SGLT2 inhibitor trials in populations with chronic kidney disease, heart failure, and type 2 diabetes at high cardiovascular risk, to compare the effects of SGLT2 inhibitors on the risk of kidney disease progression, acute kidney injury, and other key outcomes in patients with and without diabetes. Here, SLC5A2 is linked to heart failure.